- Record: found
- Abstract: found
- Article: not found
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher
1 ,
Karim Fizazi ,
Fred Saad ,
Mary-Ellen Taplin ,
Cora N Sternberg ,
Kurt Miller ,
Ronald de Wit ,
Peter Mulders ,
Kim N Chi ,
Neal D Shore ,
Andrew J Armstrong ,
Thomas W Flaig ,
Aude Fléchon ,
Paul Mainwaring ,
Mark Fleming ,
John D Hainsworth ,
Mohammad Hirmand ,
Bryan Selby ,
Lynn Seely ,
Johann S de Bono
Sep 27 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.